医学
高尿酸血症
高脂血症
胰岛素抵抗
2型糖尿病
代谢综合征
糖尿病
痛风
机制(生物学)
疾病
生物信息学
血糖性
2型糖尿病
代谢性疾病
内分泌学
内科学
药理学
尿酸
生物
哲学
认识论
出处
期刊:Life Sciences
[Elsevier]
日期:2022-07-01
卷期号:300: 120543-120543
被引量:5
标识
DOI:10.1016/j.lfs.2022.120543
摘要
Metabolic diseases, such as diabetes, gout and hyperlipidemia are global health challenges. Among them, diabetes has been extensively investigated. Type 2 diabetes mellitus (T2DM), which is characterized by hyperglycemia, is a complex metabolic disease that is associated with various metabolic disorders. The newly developed oral hypoglycemic agent, sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been associated with glucose-lowering effects and it affects metabolism in various ways. However, the potential mechanisms of SGLT2 inhibitors in metabolic diseases have not fully reviewed. Many of the effects beyond glycemic control must be considered off-target effects. Therefore, we reviewed the effects of SGLT2 inhibitors on metabolic diseases such as obesity, hypertension, hyperlipidemia, hyperuricemia, fatty liver disease, insulin resistance, osteoporosis and fractures. Moreover, we elucidated their molecular mechanisms to provide a theoretical basis for metabolic disease treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI